Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?

Kocyigit, DUYGU; YALÇIN, MUHAMMED; Gurses, Kadri; Tokgozoglu, SADBERK; KARABUDAK, RANA

doi:10.1016/j.msard.2018.11.006

Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?

Atıf İçin Kopyala

Kocyigit D., YALÇIN M. U., Gurses K. M., Tokgozoglu L., KARABUDAK R.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.27, ss.276-280, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 27
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.msard.2018.11.006
Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.276-280
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Fingolimod, a sphingosine-1-phosphate receptor agonist, is used for treatment of relapsing-remitting multiple sclerosis (RRMS). S1P receptors that fingolimod acts upon have also been shown to be expressed on atrial myocytes. This expression pattern has been linked with the drug's cardiovascular effects, such as bradycardia. We aimed to evaluate the clinical and electrocardiographic predictors of heart rate (HR) reduction in patients receiving first-dose fingolimod.